

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Activity of Oligonucleotides Containing a Biologically Active Nucleoside at the 2'End

P. Herdewijn^a; R. Charubala^b; R. Pauwels^a; E. De Clercq^a; W. Pfliegerer^b

^a Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium ^b Fakultät für Chemie, Universität Konstanz, Konstanz 1, West-Germany

To cite this Article Herdewijn, P. , Charubala, R. , Pauwels, R. , De Clercq, E. and Pfliegerer, W.(1987) 'Synthesis and Activity of Oligonucleotides Containing a Biologically Active Nucleoside at the 2'End', *Nucleosides, Nucleotides and Nucleic Acids*, 6: 1, 441 — 442

To link to this Article: DOI: 10.1080/07328318708056250

URL: <http://dx.doi.org/10.1080/07328318708056250>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND ACTIVITY OF OLIGONUCLEOTIDES CONTAINING A BIOLOGICALLY ACTIVE
NUCLEOSIDE AT THE 2'END

P. Herdewijn^{1*}, R. Charubala², R. Pauwels¹, E. De Clercq¹
and W. Pflleiderer²

¹Rega Institute for Medical Research, Katholieke Universiteit Leuven,
B-3000 Leuven, Belgium

²Fakultät für Chemie, Universität Konstanz,
D-7750 Konstanz 1, West-Germany

The antiviral activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd), acyclovir and other antiherpetic nucleosides depends on a selective phosphorylation by the herpesvirus-induced thymidine kinase in the infected cells. Viruses not encoding a specific thymidine kinase (TK) activity are resistant to the action of these nucleoside analogues. The nucleoside monophosphates are as such poorly taken up by the cells. In order to circumvent the necessity of intracellular phosphorylation, we synthesized four core oligonucleotides bearing a biological active nucleoside at the 2'end. It was hypothesized that these core oligonucleotides, like core 2-5A itself, would be taken up within the cell and that, following intracellular 2'-5' phosphodiesterase cleavage, the 5'-monophosphate of the active product would be formed. In these circumstances, activity against TK⁻ strains could be expected.

The oligonucleotides 1-4 were evaluated for their antiviral activity against different herpes viruses. However, no activity was found for the BVdUrd- and acyclovir-oligonucleotide analogues against TK⁻ herpes simplex virus (HSV) mutants. The antiviral activity of the oligonucleotide analogues against HSV-1, TK⁻ HSV-1, HSV-2 and vaccinia virus was comparable to the activity of the parent nucleosides BVdUrd, acyclovir and 5-fluoro-2'-deoxyuridine (FdUrd). This indicates that the oligonucleotides were hydrolyzed such that they did directly release the nucleosides BVdUrd, acyclovir and FdUrd but not the 5'-monophosphates thereof. By which enzyme(s) these oligonucleotides are degraded and whether they are degraded intra- or extracellularly remain issues for further study.

*Research associate of the Belgian N.F.W.O.




Table 1. Antiviral activity of oligonucleotides containing a biologically active nucleoside at the 2'end

Compound	Minimum inhibitory concentration ^a (μg/ml)			
	HSV-1	TK ⁻ HSV-1	HSV-2	Vaccinia virus
<u>1</u>	0.07	≥ 100	10	7
<u>2</u>	0.7	100	0.4	> 100
<u>3</u>	40	0.4	70	0.2
<u>4</u>	1	70	1	7
<hr/>				
2-5A	> 200	> 200	> 200	> 200
BVdUrd	0.02	≥ 100	4	10
Acyclovir	0.1	70	0.2	> 100
FdUrd	10	0.07	40	0.07

^aRequired to reduce virus-induced cytopathogenicity by 50 %. Average values for three HSV-1 strains (KOS, F, McIntyre), three HSV-2 strains (G, 196, Lyons) and two TK⁻ HSV-1 mutants (B2006, VMW-1837).